Forerunner Pharma Research is focusing to research antibody drugs for cancer therapetics.

Challenging Cancer through
Innovative Antibody Drug Discovery

Forerunner Pharma Research (FPR) is a Tokyo-based biopharmaceutical venture focusing antibody drug discovery for cancer diagnostics and therapeutics.
FPR conducts well-rounded joint research under the collaborative research agreement with the University of Tokyo Research Center for Advanced Science and Technology (RCAST). RCAST is the central hub for Japan's transcriptome studies and engaged in the world-class gene expression analysis to identify target proteins for cancer and other therapeutics.
More about What we do

This allows FPR to capitalize on the vast accumulation of competitive and latest data of academic and other institutions as well as the state of the art drug development technology of its major share holder, Chugai Pharmaceutical.
With a clear vision toward the commercialization of findings from the research, FPR strives for innovative medicines that help improve people's health and wellbeing.